On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

ChineseInvestors.com (CIIX) Achieves Exciting Firsts in the Global Cannabis Market

  • Launched world’s first Chinese language online CBD health products store
  • Launched world’s first Chinese language mobile cannabis navigation app
  • Positioned to become first company in China to use CBD oil in treating epilepsy and Alzheimer’s

Pursuing its aim of becoming the leading publicly traded Chinese medical marijuana company, ChineseInvestors.com, Inc. (OTCQB: CIIX) continues its focus on investing in distribution and R&D of cannabidiol-based (CBD) medicines and health products targeted at Chinese-speaking clients throughout the world.

Marijuana use is currently illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers in that country. CIIX is also expanding its footprint to other countries and recently incorporated CBD Biotechnology Inc. in British Columbia, Canada, which will focus on R&D and distribution of health products, including hemp-based CBD, food and beverage products there.

Additionally, CIIX officially launched a CBD online store, ChineseCBDoil.com, in December 2016 in the free-trade zone of Shanghai, China. The site went live on January 31 and is the very first CBD health products Web store to be launched in the Chinese language, offering various CBD nutritional products, such as soft gels, capsules and concentrates. The company further plans to market a line of nutrition and food products through a brick-and-mortar store in San Gabriel, California — a predominantly Chinese-speaking area and the company’s home market (http://nnw.fm/0Box5).

Concurrent with the launch of ChineseCBDoil.com, CIIX also launched the very first Chinese language mobile cannabis navigation app, which is a Yelp-style social media app containing a database of cannabis dispensaries and marijuana strains. The app also features a platform for reviewing and discussing cannabis products, maps showing marijuana dispensary locations, and summary reports of cannabis businesses in Los Angeles and other large cities. This app has already been approved by the Apple store.

CIIX’s other cannabis-related endeavors include striving to become the very first company in China to employ CBD oil as a treatment to relieve suffering for epilepsy and Alzheimer’s patients. The company plans to continue studying CBD oil’s efficacy as a treatment for these diseases and intends to invest in CBD drug R&D enterprises, with an end goal of developing a variety of CBD drugs to treat epilepsy and Alzheimer’s.

For more information, visit the company’s website at www.ChineseInvestors.com

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

Contact us: 212.418.1217